Affiliation:
1. University of Leicester College of Life Sciences
2. GSK: GlaxoSmithKline Plc
3. Sanofi
4. Karolinska Institute: Karolinska Institutet
5. JG Zebra Consulting
6. Newcastle University
7. Critical Path Institute
8. Source Health Economics
9. Duchenne UK
10. University of Warwick
Abstract
Abstract
Background
The aim of this study was to build a natural history model (NHM) for Duchenne muscular dystrophy (DMD) to provide new insights into the disease and to inform economic evaluations of new therapies. The study was conducted as part of Project HERCULES, a multi-stakeholder collaboration to develop tools to support the health technology assessment of new treatments for DMD.
Methods
Health states were identified based on a review of NHMs and input from clinicians, patients, and caregivers, and defined using outcomes commonly collected in clinical trials and real-world practice. The primary data source informing the NHM was the Critical Path Institute Duchenne Regulatory Science Consortium (D-RSC) database. This was supplemented, where data were scarce or absent, with expert input obtained via an elicitation exercise, and a systematic literature review and meta-analysis of mortality data.
Results
The NHM includes ambulatory, transfer, and non-ambulatory phases. Health states capture progression in each phase including loss of ambulation, ability to weight bear, and upper body and respiratory function, respectively. Scoliosis and cardiomyopathy were not included in health state definitions as the reporting of data in D-RSC for these diagnoses was poor. The NHM estimates that patients spend approximately 9.5 years in ambulatory states,
1.5 years in the transfer state, and the remainder of their lives in non-ambulatory states, with a median predicted survival of 29.8 years (95% CI: 29.1, 30.8).
Conclusion
The model developed includes a detailed disease pathway for DMD, including the clinically, patient, caregiver, and economically important transfer state which has not been identified or included in previous NHMs. The NHM will aid the understanding of disease milestones and may be used to support economic evaluations for new treatments for DMD, help facilitate inclusion of a lifetime time horizon within economic models and identify areas for further research.
Publisher
Research Square Platform LLC
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献